These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25145549)

  • 1. Melanoma: diagnosis, staging, and treatment. Consensus group recommendations.
    Berrocal A; Cabañas L; Espinosa E; Fernández-de-Misa R; Martín-Algarra S; Martínez-Cedres JC; Ríos-Buceta L; Rodríguez-Peralto JL
    Adv Ther; 2014 Sep; 31(9):945-60. PubMed ID: 25145549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib in melanoma.
    Shaw HM; Nathan PD
    Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
    Schaefer T; Satzger I; Gutzmer R
    Medicine (Baltimore); 2017 Jan; 96(1):e5753. PubMed ID: 28072717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
    Dean E; Lorigan P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [BRAF mutation: a novel approach in targeted melanoma therapy].
    Arenbergerová M; Puzanov I
    Klin Onkol; 2012; 25(5):323-8. PubMed ID: 23102192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Melanoma- finally good news].
    Wicki A; Arnold AW; Itin PH; Zippelius A
    Praxis (Bern 1994); 2013 May; 102(11):667-70. PubMed ID: 23692905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapies in melanoma.
    Scheier B; Amaria R; Lewis K; Gonzalez R
    Immunotherapy; 2011 Dec; 3(12):1461-9. PubMed ID: 22091682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vemurafenib and ipilimumab: new agents for metastatic melanoma.
    Banaszynski M; Kolesar JM
    Am J Health Syst Pharm; 2013 Jul; 70(14):1205-10. PubMed ID: 23820456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma.
    Buckley B; Pierce B
    JAAPA; 2018 May; 31(5):24-26. PubMed ID: 29698368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
    Lang N; Weisser A; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
    [No Abstract]   [Full Text] [Related]  

  • 15. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
    Heakal Y; Kester M; Savage S
    Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept, ipilimumab, and vemurafenib.
    Hussar DA; Au AY
    J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387
    [No Abstract]   [Full Text] [Related]  

  • 17. [Major therapeutic advances in the treatment of metastatic melanoma].
    Mateus C; Robert C
    Bull Cancer; 2012 Jun; 99(6):619-25. PubMed ID: 22652330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Translational research and diagnostics of melanoma].
    Rüschoff J; Kleinschmidt M; Middel P
    Pathologe; 2012 Nov; 33 Suppl 2():291-5. PubMed ID: 22968732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
    Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
    Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.